On the flip side, ARK’s ARKG ETF parted with a significant stake in Adaptive Biotechnologies Corp (NASDAQ: ADPT ), selling 278,792 shares worth roughly $2.65 million. This sale continues a trend from ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use a new ...

Helmholtz Munich and the University of Sydney have identified biological mechanisms that are shared across psychiatric ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

These models have shown considerable promise in tasks such as promoter prediction, enhancer identification, and gene ...

Gene expression leading to alterations in the DNA caused by asbestos exposure may explain the development of Malignant ...

Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

The global sales of microbial identification are estimated to be worth USD 4.69 billion in 2025 and anticipated to reach a value of USD 10.31 billion by 2035. Sales are projected to rise at a CAGR of ...